TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Status:
Completed
Trial end date:
2020-09-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetic
characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be
caused by gram-positive pathogens.